Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

2.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8.

3.

Transdermal estradiol and lipid profile: effects on a specific group of Brazilian postmenopausal women.

Callejon DR, Rios DR, Franceschini SA, Toloi MR.

Arq Bras Cardiol. 2009 Dec;93(6):571-5, 617-22. English, Portuguese.

4.

Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.

Stangel-Wojcikiewicz K, Zdebik A, Jach R, Huras H, Wadowska-Jaszczynska K, Radon-Pokracka M, Kempisty-Zdebik E, Ludwin A, Ludwin I.

Neuro Endocrinol Lett. 2012;33(7):697-702.

PMID:
23391877
5.

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.

L'Hermite M.

Climacteric. 2013 Aug;16 Suppl 1:44-53. doi: 10.3109/13697137.2013.808563. Review.

PMID:
23848491
7.

Hormone therapy for endometriosis and surgical menopause.

Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD005997. doi: 10.1002/14651858.CD005997.pub2. Review.

PMID:
19160262
9.

[The influence of hormone replacement therapy containing transdermal 17-beta estradiol and oral medroxyprogesterone acetate on coagulation and fibrinolysis].

Stachowiak G, Owczarek D, Połać I, Pertyński T, Jedrzejczyk S.

Ginekol Pol. 1999 Aug;70(8):527-33. Polish.

PMID:
10534929
10.

Alternative hormone replacement regimens: is there a need for further clinical trials?

Welty FK.

Curr Opin Lipidol. 2003 Dec;14(6):585-91. Review.

PMID:
14624135
11.

Estrogen, progestogens and cardiovascular risk.

Stefanick ML.

J Reprod Med. 1999 Feb;44(2 Suppl):221-6. Review.

PMID:
11392036
12.

Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.

Mueck AO.

Climacteric. 2012 Apr;15 Suppl 1:11-7. doi: 10.3109/13697137.2012.669624. Review.

PMID:
22432811
13.

Effects of postmenopausal hormone replacement therapy on body fat composition.

Yüksel H, Odabasi AR, Demircan S, Köseoğlu K, Kizilkaya K, Onur E.

Gynecol Endocrinol. 2007 Feb;23(2):99-104.

PMID:
17454160
14.

Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.

Perrone G, Stefanutti C, Galoppi P, Anelli G, Capri O, Lucani G, Vivenzio A, Mazzarella B, Zichella L.

Int J Fertil Menopausal Stud. 1996 Nov-Dec;41(6):509-15.

PMID:
9010744
15.

Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure.

Elkind-Hirsch KE, Sherman LD, Malinak R.

J Clin Endocrinol Metab. 1993 Feb;76(2):472-5.

PMID:
8432792
17.

The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.

Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R.

Br J Clin Pharmacol. 1998 Feb;45(2):170-2.

19.

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors.

Chen FP, Lee N, Soong YK, Huang KE.

Menopause. 2001 Sep-Oct;8(5):347-52.

PMID:
11528361
20.

Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants.

Tranquilli AL, Mazzanti L, Cugini AM, Cester N, Garzetti GG, Romanini C.

Gynecol Endocrinol. 1995 Jun;9(2):137-41.

PMID:
7502690

Supplemental Content

Support Center